DRMA
Dermata Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$5.51M
P/E Ratio
—
EPS
$-8.16
Beta
0.50
52W High
$9.90
52W Low
$1.10
50-Day MA
$1.29
200-Day MA
$3.30
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Dermata Therapeutics Inc
Dermata Therapeutics Inc. is a clinical-stage biotechnology company specializing in the development of innovative therapies for dermatological conditions. With its lead asset, DMT310, the company employs a novel delivery system designed to enhance treatment efficacy for acne and other skin disorders, thereby addressing significant unmet medical needs within the dermatology market. Dermata's strategically curated pipeline and proprietary technologies highlight its commitment to advancing skin health and improving patient outcomes. As the company progresses through its clinical trials, it is well-positioned to become a leader in the dermatological sector, poised to make a substantial impact on the treatment landscape for skin-related issues.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-7.86M |
| Operating Margin | 0.00% |
| Return on Equity | -194.20% |
| Return on Assets | -85.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.34 |
| Price-to-Book | 0.89 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.58 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $4.02M |
| Float | $3.17M |
| % Insiders | 24.82% |
| % Institutions | 5.39% |
Data last updated: 5/1/2026